The U.S. Food and Drug Administration has approved a low-cost generic version of liraglutide, a GLP-1 medication, offering relief to patients with Type 2 diabetes amid ongoing shortages, The Hill reported.

The green light is for patients aged 10 and older. This approval addresses the increasing demand for GLP-1 medications, particularly as brand-name versions like Victoza face widespread shortages.

Liraglutide, commonly prescribed to help control blood sugar levels, has been an essential treatment option for millions. The introduction of a generic version provides a more affordable alternative for patients, many of whom struggle with the financial burden of managing chronic conditions.

Read more at Newsmax© 2024 Newsmax. All rights reserved.